DelveInsight’s IgA nephropathy pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for IgA nephropathy treatment.New York, USA, Dec. 14, 2022 ...

Immunoglobulin A (IgA) nephropathy is the most prevalent glomerulonephritis worldwide that does not have a specific treatment. Its pathogenesis is complex and not well understood, but there is ...

OMS721 is Omeros' lead human monoclonal antibody which targets mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system. IgA ...

Session ID: 2025-08-02:346be14421bd3cbc8a9b7fc Player Element ID: vjs_video_3 ...

EP: 3. Pathogenesis of IgA Nephropathy: The 4-Hit Cascade, A Proliferation-Inducing Ligand (APRIL), and cytokines EP: 4. Diagnosing IgA Nephropathy EP: 5. Signs and Symptoms of IgA Nephropathy EP: 6.

Omeros Corporation (Nasdaq: OMER) today announced results of long-term follow-up from the Phase 2 clinical trial evaluating its MASP-2 inhibitor narsoplimab in patients with IgA nephropathy.

Gastrointestinal symptoms: In about 35% of cases, IgA nephropathy causes digestive symptoms such as diarrhea (loose and watery stools), cramping, and abdominal pain.

IgA nephropathy is the most common primary glomerulopathy globally, with an estimated 120,000 to 180,000 cases in the U.S. alone, and accounts for up to 10 percent of all dialysis patients.

Source Reference: Perkovic V, et al "Alternative complement pathway inhibition with iptacopan in IgA Nephropathy" N Engl J Med 2024; DOI: 10.1056/NEJMoa2410316.

Immunoglobulin A (IgA) nephropathy is the most prevalent glomerulonephritis worldwide that does not have a specific treatment. Its pathogenesis is complex and not well understood, but there is ...